Vunakizumab for moderate to severe plaque psoriasis
Treatments studied
Part of Skin clinical trials.
This study tests a new biologic medicine called vunakizumab for people with moderate to severe plaque psoriasis whose current biologic treatment isn't working well enough. The goal is to see if switching to vunakizumab can improve skin symptoms and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with moderate to severe plaque psoriasis.
- You have been on a biologic treatment for at least 12 weeks before the study starts.
- Your doctor agrees that switching to a different biologic (like vunakizumab) is appropriate for you.
- You have never taken a type of medicine called an IL-17A inhibitor (like secukinumab, ixekizumab, or brodalumab) and had it stop working or cause side effects that made you stop.
- If you are able to have children, you must agree to use highly effective birth control during the study and for 20 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called vunakizumab to see if it is safe and works well for people with moderate to severe plaque psoriasis. If you have not used biologic treatments before and meet other health requirements, you may be able to join.
This study tests a new medicine (HS-20137) for moderate-to-severe plaque psoriasis, a condition causing thick, scaly patches on the skin. It aims to see if this medicine can safely reduce the severity of psoriasis and improve quality of life.
This trial tests a new drug called Vunakizumab for people with mild to moderate lupus that affects the skin or joints. It aims to see if adding this drug to your current treatment can help control symptoms better.
This trial tests a new medicine called vunakizumab for various inflammatory skin diseases like eczema or psoriasis. If you have such a conditionwit, this study may help see how well the treatment works for you.
This study tests a new biologic drug called Vunakizumab for people with spondyloarthritis, a type of arthritis that affects the spine and joints. It aims to see if it can reduce inflammation and improve symptoms.
This study tests two new medications given together—one that calms the immune system to treat psoriasis and another that lowers cholesterol. If you have both moderate-to-severe plaque psoriasis and high cholesterol, this combination may help clear your skin and improve your heart health.
Hear when a new Moderate to Severe Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.